Pennsylvania-based Levolta Pharmaceuticals has entered into an exclusive licensing and distribution agreement with Saudi Arabia company, Tabuk Pharmaceutical Manufacturing Company to start commercializing a therapy for osteoarthritis (OA).
A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
With an increase in clinical studies demanding an increase in CRAs, we spoke to Sara Brannon, director of quality and training development, at ICON, to find out their approach to recruiting and how the industry is suffering due to a global shortage because...
A small molecule drug has been recommended by England’s National Institute for Health Care and Excellence (NICE) for the treatment of adults with moderate to severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis.
A company focusing on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases announced the initiation of dosing for its lead asset THN391Monday (May 15) .
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
The UK Government has announced plans to allow patients in England to receive prescription medicines directly from pharmacies without the need for a GP appointment.
Two contract research organizations working in the clinical trial and research fields have benefited from investment from Iberian private equity firm, Henko Partners.
Symptom improvements have been hailed as ‘very compelling’ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
The two French-based companies announced a strategic collaboration at the end of last month (March 2023) that saw Galapagos’ employees working in the research and discovery departments and transferred across to the contract research organization (CRO)....
Finding a treatment for a skin disease that significantly diminishes the quality of life for those living with it has moved forward to the next phase of trials.
Amid uncertainty over the future of clinical trials in the UK, the MHRA announces that it will streamline the process of running trials to make the country a more ‘attractive destination’.
Despite diversity being spoken about more than ever before, research discovers clinical trials are less representative of the US population compared to a decade prior.
Oversubscribed, series B financing for Noema Pharma’s clinical stage assets has been successfully closed raising $112 million from new and existing investors.
Two men have been jailed and another handed a suspended sentence, for selling more than three million doses of prescription-only and unlicensed medicines, including controlled medicines.
The company is using a ‘lab-in-the-loop’ process to advance the drug discovery process, and stated that opening a new lab space represents a step forward on its path to ‘transform drug discovery’.
With several reports into the UK clinical trial landscape finding serious cause for concern, the government orders a review to “resolve key challenges” facing the sector.
Recruiting and retaining patients on trials is one of the biggest hurdles the pharma industry faces, we spoke to Jonathan Eilberg to find out why and ways to tackle the ongoing issues.
The US Food and Drug Administration (FDA) has accepted Merck’s Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in kidney transplant patients for priority review.
The company announces an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce.
A study has shown that the use of exhaled volatile organic compounds (VOCs) can be used as biomarkers for differentially identifying liver disease on breath.
Here at OutsourcingPharma, we put our audience at the heart of what we do. For many years, we have provided our readers with a 360-degree view of the pharma landscape and our editorial standards remain unsurpassed.
Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...
Evidence shows that animal models currently dominating bioavailability estimates are poor predictors and human, cell-based multi-organ microphysiological systems (MPS) should be investigated, CN Bio says.
A Florida doctor has been sent to prison after submitting a false affidavit claiming she had screened children in a clinical study looking at the effectiveness of drugs given to children with asthma when she had not.
The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
Clinical operations digital maturity, capability prioritization, and best practice adoption vary widely at the world’s largest pharma firms, according to a survey of senior leaders at the companies.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
A leader from healthcare commercial intelligence company Definitive Healthcare discusses the rise of precision medicine and the benefits the field can yield.
The past two years have been full of shifts and shakes in the drug development field, but the change at Outsourcing-Pharma is easy and one for the better.
Former Medable vice president Brian Ongioni has joined the trial tech provider as vice president of product, continuing a quest for patient-focused solutions.
Leaders from the biotech company share advice on how such organizations can make the most of often limited resources via smart strategy and collaboration.
The pharma manufacturing specialist is increasing capacity at its development and manufacturing labs to meet growing global demand for highly potent APIs.
Returning to an in-person format March 21-24, the industry event is bringing a range of networking, educational, and social programming to New York City.
Created via a joint effort with EY, the pharmaceutical company launched ASPIREs, a program intended to improve its clinical trial processes in numerous areas.
A leader from health tech solutions company Vytal examines supply chain challenges faced in the pharmaceutical field and shares some potential solutions.